Next |
home / stock / aim / aim message board
Subject | By | Source | When |
---|---|---|---|
https://www.otcmarkets.com/stock/AIM | mick | investorshub | 04/30/2023 11:44:57 PM |
AIM AIM ImmunoTech Inc | mick | investorshub | 04/30/2023 9:05:07 PM |
AIM AIM ImmunoTech Inc | mick | investorshub | 04/15/2023 3:05:10 PM |
$AIM $AIM ImmunoTech Inc | mick | investorshub | 02/27/2023 12:02:09 AM |
$AIM $AIM ImmunoTech Inc | mick | investorshub | 02/06/2023 12:10:26 AM |
$AIM $AIM ImmunoTech Inc | mick | investorshub | 02/06/2023 12:10:25 AM |
They have one fda approved drug patent has | lowfloatwayne | investorshub | 01/22/2023 9:17:39 PM |
znewcar1: $AIM 22% v2,3M c.77 f48,082M H.7744 ML.291 YL.6 | znewcar1 | investorshangout | 01/17/2023 10:17:17 PM |
znewcar1: $AIM 26% v1,1M c.4083 f48,082M H.4299 ML.291 | znewcar1 | investorshangout | 01/04/2023 9:19:02 PM |
This company looks like they have some good | Sesh | investorshub | 01/04/2023 7:27:40 AM |
$AIM $AIM ImmunoTech Inc | mick | investorshub | 12/18/2022 10:53:13 PM |
$AIM $AIM ImmunoTech Inc | mick | investorshub | 10/23/2022 6:22:44 PM |
$AIM Aerosonic Common Stock ($0.40 Par Value) | mick | investorshub | 08/31/2022 11:32:17 PM |
This is the $AIM I see... | BooDog | investorshub | 08/25/2022 6:11:06 PM |
dis is good stuff Phase 2 Study of Ampligen | mick | investorshub | 08/25/2022 5:57:40 PM |
Aug-18-22 09:05AM | mick | investorshub | 08/25/2022 5:55:00 PM |
$AIM Aerosonic Common Stock ($0.40 Par Value) | mick | investorshub | 08/25/2022 5:52:35 PM |
lot in pipeline too | mick | investorshub | 08/25/2022 5:52:00 PM |
Just stumbled on this one Mick. | BooDog | investorshub | 08/25/2022 11:11:24 AM |
$AIM ImmunoTech to Present at the Virtual Investor | mick | investorshub | 07/17/2022 10:10:17 PM |
News, Short Squeeze, Breakout and More Instantly...
AIM ImmunoTech Inc. Company Name:
AIM Stock Symbol:
NYSE Market:
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), today announced that Thomas K. Equels, ...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), today announced that Thomas K. Equels, ...